ILMN Illumina Inc
Company Analysis
Latest News
🔴 Illumina falls 4.1% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
Illumina attracts institutional buyers despite director’s $145 million stock sale
Several institutional investors recently established new positions in Illumina. Patient Capital Management LLC acquired 345,314 shares valued at approximately...
🟢 Illumina is trading 5% up today after broad biotech rally
Illumina is trading now at $215.64, up 5.19%, following investor enthusiasm after Moderna and Merck’s positive Phase 3 personalized mRNA cancer-vaccine results...
🟢 Illumina rises 5.8% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Illumina Completes $300M Public Offering of 4.950% Notes Due 2029
Illumina announced the completion of a public offering of $300 million in senior notes. The company intends to use the net proceeds, combined with cash on...
Illumina Director Sells $148 Million Stake in Year’s Largest Insider Trade
Illumina, Inc. Independent Director Keith Meister sold a block of shares worth approximately $148 million. The transaction was executed at a price of roughly...
Illumina Reaches No-Payment Settlement with Icahn in GRAIL Acquisition Lawsuit
Illumina, along with several current and former directors, has entered into a settlement agreement to dismiss the lawsuit filed by Icahn Partners LP concerning...
🔴 Illumina is trading 5% down today with no clear company-specific catalyst
Illumina is trading at $188.77 (-4.79%) after no clear company-specific catalyst emerged in August 6, 2026 coverage. • The latest confirmed company event was...
🔴 Illumina is trading 4.1% down today on profit-taking and broader biotech weakness
Illumina is trading 4.1% down at $196.74 on post-earnings profit-taking and broader biotech sector weakness. • The company beat Q2 expectations and raised its...
Illumina's second quarter revenue of $1.16B beats estimates, prompting a raised full-year 2026 outlook.
Illumina reported second quarter 2026 revenue of $1.16 billion, up 9.5% year-over-year, and non-GAAP diluted EPS of $1.31. These results exceeded analyst...
🟢 Illumina is trading 4.1% up today ahead of Q2 earnings release
Illumina is trading 4.1% up at $202.76 as investors position themselves ahead of the company’s Q2 2026 earnings release scheduled for after the market...
Illumina Inc Q2 2026 Earnings Preview: What Analysts Expect on July 30, 2026
Illumina is projected to report Q2 2026 revenue of $1.12 billion and EPS of $1.23, as the current stock price of $128.45 seeks to close the gap toward the...
🔴 Illumina is trading 5.3% down today on broad tariff concerns and a tech-led pullback
Illumina is trading 5.3% down at $186.41 in pre-market action as markets digest new broad U.S. tariffs and a tech-led retreat. • The decline follows a...
🟢 Illumina is trading 4.08% up today as shares gain momentum following new executive appointments
Illumina is trading at $195.47 (+4.08%) today. • The company announced the appointments of Mike Sullivan as Chief Commercial Officer and Julie Coletti as...
🔴 ILMN is trading 5.2% down today on a post-earnings pullback following a recent guidance-driven surge
ILMN is trading 5.2% down at $181.71 in pre-market as investors reassess the stock's valuation following a significant rally triggered by its latest financial...
🔴 ILMN Shares Fall 5% in After-Hours Trading Despite Piper Sandler Price Target Raise
• Illumina (ILMN) is trading at $175.10, down approximately 5% in after-hours trading, retracing from its recent multi-day rally. • This decline occurs despite...
🟢 ILMN extends move to 5.0% up
ILMN is trading at $184.66, up 5.0% versus the comparison close of $175.83 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 ILMN is trading 4.1% up today after Guggenheim and Piper Sandler raise price targets
• ILMN is trading 4.1% up now at $182.98, with gains driven by fresh bullish analyst commentary from Guggenheim and Piper Sandler. • Both Guggenheim and Piper...
🟢 Illumina Inc is trading 4.19% up
ILMN is trading at $182.43, up 4.19%.
🟢 ILMN extends move to 6.2% up
ILMN is trading at $175.12, up 6.2% versus the comparison close of $164.93 during regular trading. This is a price-movement alert; no separate company-specific...